ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831

Its studies are mostly in Immunoglobulin G4-Related Disease · Burkitt Lymphoma, led by Acepodia Biotech.

Drug pageAllogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 27, 20252 company-led studies, 1 open or runningNext primary completion: Sep 20, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acepodia Biotech21 open or runningphase 2since May 27, 2025Nov 2, 2022Sep 20, 2029phase 2 · NCT07061938

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2022First study: phase 1 study in Lymphoma, B-CellFirst studyNCT05653271 · 16 enrolled · United States, Hong Kong, Taiwan
  2. May 27, 2025Phase 2 study in Immunoglobulin G4-Related DiseaseNCT07061938 · 34 enrolled · United States, China, Japan

Ahead

  1. Sep 20, 2029Primary completion: phase 2 study in Immunoglobulin G4-Related DiseaseNCT07061938

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07061938Immunoglobulin G4-Related Disease · United States, China, Japan2Active, not recruitingSep 20, 202934
NCT05653271Lymphoma, B-Cell · United States, Hong Kong, Taiwan1CompletedMar 31, 202616

How it is read

Names in the registry

  • “ACE1831”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.